| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
196,220,000 |
| Market
Cap: |
193.16(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.73 - $3.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Co.'s first two products were approved by the U.S. Food and Drug Administration, European Medicines Agency, and Swiss Agency for Therapeutic Products. Bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
44,241 |
63,638 |
100,262 |
107,370 |
| Total Sell Value |
$49,636 |
$78,883 |
$157,378 |
$175,963 |
| Total People Sold |
4 |
4 |
5 |
5 |
| Total Sell Transactions |
5 |
12 |
22 |
28 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Looker Benjamin |
General Counsel |
• – – |
2025-06-17 |
4 |
S |
$1.15 |
$7,398 |
D/D |
(6,422) |
401,241 |
|
9% |
|
| Halladay Benjamin |
Chief Financial Officer |
• – – |
2025-06-17 |
4 |
S |
$1.15 |
$8,328 |
D/D |
(7,229) |
474,473 |
|
9% |
|
| Koenig Sheldon L. |
President and CEO |
• • – |
2025-06-17 |
4 |
S |
$1.11 |
$33,796 |
D/D |
(30,474) |
1,541,488 |
|
9% |
|
| Rocamboli Stephen |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
33,000 |
69,261 |
|
- |
|
| Hoffman Robert |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
5,280 |
5,280 |
|
- |
|
| Fischer Seth H.z. |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
33,000 |
61,150 |
|
- |
|
| Shepard Jay |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
33,000 |
84,599 |
|
- |
|
| Carroll J Martin |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
33,000 |
97,650 |
|
- |
|
| Halladay Benjamin |
Chief Financial Officer |
• – – |
2025-04-17 |
4 |
S |
$0.96 |
$8 |
D/D |
(8) |
481,702 |
|
-5% |
|
| Warren Eric |
Chief Commercial Officer |
• – – |
2025-04-17 |
4 |
S |
$0.98 |
$106 |
D/D |
(108) |
370,218 |
|
-5% |
|
| Halladay Benjamin |
Chief Financial Officer |
• – – |
2025-03-18 |
4 |
S |
$1.48 |
$5,242 |
D/D |
(3,535) |
481,710 |
|
37% |
|
| Warren Eric |
Chief Commercial Officer |
• – – |
2025-03-18 |
4 |
S |
$1.49 |
$3,618 |
D/D |
(2,433) |
370,326 |
|
37% |
|
| Koenig Sheldon L. |
President and CEO |
• • – |
2025-03-18 |
4 |
S |
$1.50 |
$19,623 |
D/D |
(13,047) |
1,571,962 |
|
37% |
|
| Looker Benjamin |
General Counsel |
• – – |
2025-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
224,000 |
407,663 |
|
- |
|
| Koenig Sheldon L. |
President and CEO |
• • – |
2025-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
840,000 |
1,585,009 |
|
- |
|
| Halladay Benjamin |
Chief Financial Officer |
• – – |
2025-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
238,000 |
485,245 |
|
- |
|
| Warren Eric |
Chief Commercial Officer |
• – – |
2025-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
213,000 |
372,759 |
|
- |
|
| Halladay Benjamin |
Chief Financial Officer |
• – – |
2025-02-19 |
4 |
S |
$1.86 |
$20 |
D/D |
(11) |
240,671 |
|
48% |
|
| Warren Eric |
Chief Commercial Officer |
• – – |
2025-02-19 |
4 |
S |
$1.87 |
$446 |
D/D |
(239) |
159,759 |
|
48% |
|
| Halladay Benjamin |
Chief Financial Officer |
• – – |
2025-01-17 |
4 |
S |
$2.27 |
$20 |
D/D |
(9) |
240,682 |
|
61% |
|
| Warren Eric |
Chief Commercial Officer |
• – – |
2025-01-17 |
4 |
S |
$2.26 |
$278 |
D/D |
(123) |
159,998 |
|
61% |
|
| Warren Eric |
Chief Commercial Officer |
• – – |
2024-12-17 |
4 |
S |
$2.43 |
$5,426 |
D/D |
(2,234) |
160,121 |
|
59% |
|
| Koenig Sheldon L. |
President and CEO |
• • – |
2024-12-17 |
4 |
S |
$2.47 |
$30,694 |
D/D |
(12,447) |
739,819 |
|
59% |
|
| Halladay Benjamin |
Chief Financial Officer |
• – – |
2024-12-17 |
4 |
S |
$2.42 |
$7,866 |
D/D |
(3,245) |
240,691 |
|
59% |
|
| Warren Eric |
Chief Commercial Officer |
• – – |
2024-11-19 |
4 |
S |
$2.17 |
$427 |
D/D |
(197) |
162,355 |
|
42% |
|
221 Records found
|
|
Page 1 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (0.93%) 
